Your session is about to expire
← Back to Search
Behavioural Intervention
Cognitive Training for ADHD
N/A
Recruiting
Research Sponsored by Florida State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up immediate post-treatment (within 2 weeks of final treatment session)
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new computer program called Central Executive Training (CET) to help kids with ADHD improve their memory and attention. The program uses fun computer games to practice these skills. It was developed with input from experts, caregivers, and kids with ADHD. Central Executive Training (CET) has been shown to improve executive function deficits and behavioral symptoms in children with ADHD.
Who is the study for?
This trial is for children aged 8-12 with ADHD, as confirmed by clinical interviews and teacher/parent ratings. They must have below-average working memory but no severe neurological issues, intellectual disability (IQ < 78), or conditions like psychosis that could affect participation. Non-English speakers are excluded.
What is being tested?
The study tests Central Executive Training (CET) targeting different executive functions in the brain to improve attention and memory in kids with ADHD. It's a computerized program developed from expert feedback, designed to help manage symptoms of ADHD through cognitive exercises.
What are the potential side effects?
Since CET involves non-invasive cognitive training exercises on a computer, there are typically no physical side effects associated with this type of intervention.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ immediate post-treatment (within 2 weeks of final treatment session)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~immediate post-treatment (within 2 weeks of final treatment session)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
ADHD symptoms
Secondary study objectives
Actigraph-measured hyperactivity during baseline
Actigraph-measured hyperactivity during working memory testing
Inhibitory control
+1 moreOther study objectives
Academic performance rating scale (APRS)
Children's Organizational Skills Scale (COSS) Parent Report
Children's Organizational Skills Scale (COSS) Teacher Report
+9 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: CET-Working Memory (WM)Experimental Treatment1 Intervention
Central Executive Training: Working Memory
Group II: CET-Behavioral Inhibition (BI)Active Control1 Intervention
Central Executive Training: Inhibitory Control
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for ADHD include stimulant medications, cognitive behavioral therapy (CBT), and emerging interventions like Central Executive Training (CET). Stimulant medications, such as methylphenidate and amphetamines, increase dopamine and norepinephrine levels in the brain, improving attention and focus.
CBT helps patients develop coping strategies and organizational skills to manage symptoms. CET specifically targets components of the working memory system to enhance executive functions, which are often impaired in ADHD patients.
These mechanisms are important as they address various aspects of ADHD, offering a multifaceted approach to treatment.
Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.[Effect of methylphenidate on executive function for children with attention deficit hyperactivity disorder].
Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.[Effect of methylphenidate on executive function for children with attention deficit hyperactivity disorder].
Find a Location
Who is running the clinical trial?
Florida State UniversityLead Sponsor
223 Previous Clinical Trials
36,505 Total Patients Enrolled
3 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
554 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- The parent and teacher ratings for ADHD-RS-5 or BASC-3 Attention Problems/Hyperactivity subscales were in the clinical/borderline range based on age and gender.This study is looking for people with ADHD who have a working memory that is below average or lower than normal on at least one pre-treatment WM test.
Research Study Groups:
This trial has the following groups:- Group 1: CET-Working Memory (WM)
- Group 2: CET-Behavioral Inhibition (BI)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.